account_balance
Investment manager · 13F filer · SEC CIK 1381843
Atle Fund Management AB
Reported value$373Mas of Sep 30, 2026
Positions39 4 new, 4 sold out
Top 10 weight53.9%LLY alone is 10%
FiledNov 1243 days after quarter end
Portfolio · as of Sep 30, 2026
Where the money is
New or addedTrimmedHeld
LLYEli Lilly & Co
9.7%Added +5%
MRKMerck & Co. Inc
6.6%Trimmed −11%
JNJJohnson & Johnson
6.5%Added +7%
ABBVAbbvie Inc
6.4%Added +42%
TMOThermo Fisher Scientific Corp
6.2%Added +24%
BIIBBiogen Inc
4.3%Added +13%
VRTXVertex Pharmaceuticals Inc
3.9%Added +47%
RVMDRevolution Medicines Inc
3.6%Trimmed −10%
ONCBeone Medicines Ltd-adr
3.5%
CVSCVS Health Corp
3.2%Trimmed −5%
CORCencora Inc
2.9%Added +16%
BBIOBridgebio Pharma Inc
2.9%Added +31%
LLYEli Lilly & Co
9.7%Added +5%
MRKMerck & Co. Inc
6.6%Trimmed −11%
JNJJohnson & Johnson
6.5%Added +7%
ABBVAbbvie Inc
6.4%Added +42%
TMOThermo Fisher Scientific Corp
6.2%Added +24%
BIIB4.3%VRTX3.9%RVMD3.6%ONC3.5%CVS3.2%COR2.9%BBIO2.9%Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
LLY Eli Lilly & Co 9.7% Added +5%MRK Merck & Co. Inc 6.6% Trimmed −11%JNJ Johnson & Johnson 6.5% Added +7%ABBV Abbvie Inc 6.4% Added +42%TMO Thermo Fisher Scientific Corp 6.2% Added +24%BIIB Biogen Inc 4.3% Added +13%VRTX Vertex Pharmaceuticals Inc 3.9% Added +47%RVMD Revolution Medicines Inc 3.6% Trimmed −10%ONC Beone Medicines Ltd-adr 3.5% HeldCVS CVS Health Corp 3.2% Trimmed −5%COR Cencora Inc 2.9% Added +16%BBIO Bridgebio Pharma Inc 2.9% Added +31%
What changed